Category Archives: Business of Biotech

A Start-Up Model Worthy of Consideration

attendessBusinessForum

Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall Street Journal’s Brian Gormley recently talked to Albert L. Sokol, a partner with Edwards Wildman Palmer, about the two venture-backed biotechs – Forma Therapeutics and Viamet Pharmaceuticals – that he helped convert to LLCs. In the WSJ article – Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says – Sokol describes the benefits to start-ups and their venture investors, as Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Colorado Biotech’s Big Day

biowest

Last week, the Colorado BioScience Association (CBSA) hosted its annual BioWest Conference – a one day event attended by more than 500 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. Colorado Public Radio’s Ryan Warner interviewed CBSA’s April Giles about the conference and several innovative biotech companies in the state. Give it a listen.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

New Report Shows Strength of Massachusetts’ Biotech Industry

arrow

If you read this blog, there’s a good chance you already know that Massachusetts is one of the biggest biotech hubs in the world. The Commonwealth’s successes in biotech economic development can be attributed to a number of things. Perhaps foremost, its world-class universities, such as MIT and Harvard, continue to churn out the innovation that keeps venture groups interested. Meanwhile, established biotechs and Big Pharma continue to focus more and more R&D work in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Award Honors Rhode Island Biotech Excellence

RI_imagelogo

Know somebody in Rhode Island biotech that deserves special recognition? Then nominate them for Tech Collective’s Rhode Island Bioscience Awards. Check it out, nominate, and apply here. Nominations are due September 24th, Applications are due October 1st.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Managing in a Cost-Constrained Environment

medicine

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,